Mesoporous Bioactive Glass-Incorporated Injectable Strontium-Containing Calcium Phosphate Cement Enhanced Osteoconductivity in a Critical-Sized Metaphyseal Defect in Osteoporotic Rats

Research output: Contribution to journalResearch articleContributedpeer-review


  • Seemun Ray - , Justus Liebig University Giessen (Author)
  • Ulrich Thormann - , Justus Liebig University Giessen (Author)
  • Inga Kramer - , Justus Liebig University Giessen (Author)
  • Ursula Sommer - , Justus Liebig University Giessen (Author)
  • Matthäus Budak - , Justus Liebig University Giessen (Author)
  • Matthias Schumacher - , University Hospital Carl Gustav Carus Dresden (Author)
  • Anne Bernhardt - , Centre for translational bone, joint and soft tissue research (Author)
  • Anja Lode - , Centre for translational bone, joint and soft tissue research (Author)
  • Christine Kern - , Justus Liebig University Giessen (Author)
  • Marcus Rohnke - , Justus Liebig University Giessen (Author)
  • Christian Heiss - , Justus Liebig University Giessen (Author)
  • Katrin S Lips - , Justus Liebig University Giessen (Author)
  • Michael Gelinsky - , Centre for translational bone, joint and soft tissue research (Author)
  • Volker Alt - , Justus Liebig University Giessen (Author)


In this study, the in vitro and in vivo bone formation behavior of mesoporous bioactive glass (MBG) particles incorporated in a pasty strontium-containing calcium phosphate bone cement (pS100G10) was studied in a metaphyseal fracture-defect model in ovariectomized rats and compared to a plain pasty strontium-containing calcium phosphate bone cement (pS100) and control (empty defect) group, respectively. In vitro testing showed good cytocompatibility on human preosteoblasts and ongoing dissolution of the MBG component. Neither the released strontium nor the BMG particles from the pS100G10 had a negative influence on cell viability. Forty-five female Sprague-Dawley rats were randomly assigned to three different treatment groups: (1) pS100 (n = 15), (2) pS100G10 (n = 15), and (3) empty defect (n = 15). Twelve weeks after bilateral ovariectomy and multi-deficient diet, a 4 mm wedge-shaped fracture-defect was created at the metaphyseal area of the left femur in all animals. The originated fracture-defect was substituted with pS100 or pS100G10 or left empty. After six weeks, histomorphometrical analysis revealed a statistically significant higher bone volume/tissue volume ratio in the pS100G10 group compared to the pS100 (p = 0.03) and empty defect groups (p = 0.0001), indicating enhanced osteoconductivity with the incorporation of MBG. Immunohistochemistry revealed a significant decrease in the RANKL/OPG ratio for pS100 (p = 0.004) and pS100G10 (p = 0.003) compared to the empty defect group. pS100G10 showed a statistically higher expression of BMP-2. In addition, a statistically significant higher gene expression of alkaline phosphatase, osteoprotegerin, collagen1a1, collagen10a1 with a simultaneous decrease in RANKL, and carbonic anhydrase was seen in the pS100 and pS100G10 groups compared to the empty defect group. Mass spectrometric imaging by time-of-flight secondary ion mass spectrometry (ToF-SIMS) showed the release of Sr2+ ions from both pS100 and pS100G10, with a gradient into the interface region. ToF-SIMS imaging also revealed that resorption of the MBG particles allowed for new bone formation in cement pores. In summary, the current work shows better bone formation of the injectable pasty strontium-containing calcium phosphate bone cement with incorporated mesoporous bioactive glass compared to the bioactive-free bone cement and empty defects and can be considered for clinical application for osteopenic fracture defects in the future.


Original languageEnglish
Article number1203
Issue number10
Publication statusPublished - 16 Oct 2023

External IDs

PubMedCentral PMC10604136
ORCID /0000-0001-9075-5121/work/146165219
Scopus 85175156737